Subscribe

Spotlight -

This Year In Medicine 2025

John Stone, MD, MPH

John Stone, MD, MPH

Stone is professor of medicine at Harvard Medical School and the Edward A Fox Chair in Medicine at the Massachusetts General Hospital. He has treated IgG4-related disease (IgG4-RD) since its emergence in recent years and is passionate about educating patients and fellow healthcare providers (HCPs) about the indolent and systemic nature of this disease.

Articles by John Stone, MD, MPH

Hope on the Horizon: The Future of GCA Treatment

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 29th 2026

Reflecting on Trial Limitations in GCA: Painting a Future for IL-17A Targeting Therapies

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 29th 2026

Experts Discuss the REPLENISH Trial for Polymyalgia Rheumatica

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 22nd 2026

The Trial Design and Interim Results From the GCAptAIN Trial

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 22nd 2026

Clinical Experience with Tocilizumab and Upadacitinib in GCA Treatment

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 15th 2026

Reflecting on the Trial Landscape in GCA and History of Approved Agents

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 15th 2026

Current Pathway Treatment Targets in GCA

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 8th 2026

Real-World Complications Using Steroids to Treat GCA

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

January 8th 2026

Current Standards of Care in GCA Treatment

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 24th 2025

The Physical and Mental Quality of Life Impacts of GCA

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 24th 2025

Expert Perspectives on the Reasons for Diagnostic Delay in GCA

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 17th 2025

Diagnostic Blood Testing in GCA

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 17th 2025

Discussing the Overlap of Polymyalgia Rheumatica in Patients With GCA

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 10th 2025

Imaging Modalities for Diagnosing GCA: What Clinicians are Doing in Clinic

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 10th 2025

Non-Cranial Symptoms in GCA

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 3rd 2025

Current Gaps in Diagnostic Criteria Standards: Key Factors That Inform Diagnostic Decisions

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

December 3rd 2025

The Underlying Causes of GCA: Environmental and Genetic Factors

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

November 24th 2025

An Overview of Giant Cell Arteritis (GCA): Common Signs and Symptoms

ByRobert Spiera, MD,John Stone, MD, MPH,Anisha Dua, MD, MPH,Leonard Calabrese, DO

November 24th 2025

Latest Updated Articles

Trending on HCPLive

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Skin of Color Savvy: Reimbursement, Coverage, and Care Gaps for Patients With Skin of Color

Brelovitug Meets Primary Endpoint in Phase 3 AZURE-1 Hepatitis Delta Trial

Efsitora Dosing and Titration in Type 2 Diabetes